|
Contraindications
Patient w/ active meningeal infection.
|
|
Special Precautions
Patient w/ previous drug-induced bone marrow suppression. Renal or hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor LFTs, CBC w/ differential and platelet count, BUN, serum uric acid, serum creatinine. Monitor for signs of an immediate reaction, chemical arachnoiditis, neurotoxicity.
|
|
Adverse Reactions
Nausea, vomiting, fever, rash, diarrhoea, anorexia, oral and anal inflammation or ulceration, hepatic dysfunction, headache, weakness, confusion, thrombocytopenia, fatigue.
Potentially Fatal: Chemical arachnoiditis, bone marrow suppression. Viral, fungal, bacterial, saprophytic or parasitic infections. Pulmonary toxicity, sudden resp distress syndrome and pulmonary oedema (high-doses). |
|
Drug Interactions
May reduce efficacy of 5-fluorocytosine, digoxin, gentamicin. May increase risk of neurotoxicity w/ other cytotoxic agents (intrathecal).
|
|
CIMS Class
|
|
ATC Classification
L01BC01 - cytarabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.
|
Sign Out
